You are here

Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial

Dino Amadori, Massimo Aglietta, Barbara Alessi, Lorenzo Gianni, Toni Ibrahim, Gabriella Farina, Fernando Gaion, Francesco Bertoldo, Daniele Santini, Roberta Rondena, Paola Bogani, Carla I Ripamonti

The Lancet Oncology, Volume 14, Issue 7, Pages 663 - 670, June 2013

Editors' comments: Dr. A.Snegovoy

I absolutely agree with reply Brian Hutton, Christina L Addison, Mark Clemons on the ZOOM trial: ““one size fits all” approach to treatment with bone-targeted agents is no longer appropriate in an era of increasingly personalised medicine”. 
The most common question asked by oncologists, after listening to presentations on bone-modifying agents (BMA: bisphosphonate & RANK-ligand inhibitor) is: the problem of the duration of use of the BMA and the possibility of increasing or reducing the dose of BMA. This is due to the risk of increasing the frequency of osteonecrosis of the mandible, the financial aspects, as well as the lack of clearly defined treatment duration BMA.
This is the first study that presents an opportunity to answer the question increasing interval bisphosphonate introduction in the second year of treatment, which is very interesting for the daily practice of treatment.